^
Association details:
| Biomarker: | BRCA2 mutation |
|---|---|
| Cancer: | Breast Cancer |
| Drug: | nesuparib (JPI-547) (PARP inhibitor, TNKS inhibitor) |
| Direction: | Sensitive |
Evidence:
Source:
Title:
A phase I dose-escalation and expansion study of JPI-547, a dual inhibitor of PARP/tankyrase in patients with advanced solid tumors.
Published date:
05/19/2021
Excerpt:
This is the first in human (FIH) phase I study of JPI-547 in patients (pts) with advanced solid tumors….At the time of data cut-off, three pts were ongoing as following response and cancer types:...cPR (NSCLC, gBRCA2m, 3.8 mos)...
DOI:
10.1200/JCO.2021.39.15_suppl.3113
Trial ID:
